...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

Nextblockbuster

We are in the same boat. Take it for what it's worth - promises, promises, promises.

Share
New Message
Please login to post a reply